Ernexa Therapeutics Inc. (ERNAW) — SEC Filings
Ernexa Therapeutics Inc. (ERNAW) — 33 SEC filings. Latest: 8-K (Dec 11, 2025). Includes 19 8-K, 6 10-Q, 2 DEF 14A.
View Ernexa Therapeutics Inc. on SEC EDGAR
Overview
Ernexa Therapeutics Inc. (ERNAW) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Dec 11, 2025: On December 11, 2025, Ernexa Therapeutics Inc. filed an 8-K report. The filing primarily serves as a notification of financial statements and exhibits, and a Regulation FD disclosure. No specific material events or financial figures were detailed in the provided excerpt.
Sentiment Summary
Across 33 filings, the sentiment breakdown is: 7 bearish, 25 neutral, 1 mixed. The dominant filing sentiment for Ernexa Therapeutics Inc. is neutral.
Filing Type Overview
Ernexa Therapeutics Inc. (ERNAW) has filed 19 8-K, 6 10-Q, 2 DEF 14A, 2 10-K, 1 S-1, 1 10-K/A, 2 SC 13G/A with the SEC between Jan 2024 to Dec 2025.
Filings by Year
Recent SEC Filings (33)
Risk Profile
Risk Assessment: Of ERNAW's 30 recent filings, 6 were flagged as high-risk, 16 as medium-risk, and 8 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $0 |
| Net Income | -$1.2M |
| EPS | N/A |
| Debt-to-Equity | N/A |
| Cash Position | $3.0M |
| Operating Margin | N/A |
| Total Assets | N/A |
| Total Debt | N/A |
Key Executives
- Mr. Luther
- Dr. Angel
- Dr. Federoff
- Sanjeev Luther
Industry Context
The biotechnology sector is characterized by high R&D costs, long development cycles, and significant regulatory hurdles. Companies like Ernexa often operate at a loss for extended periods, relying heavily on external financing to fund research and clinical trials. The competitive landscape is intense, with many companies vying for breakthroughs in unmet medical needs.
Top Tags
corporate-governance (6) · delisting (5) · equity-sale (4) · 10-Q (4) · material-agreement (4) · Biotechnology (3) · Eterna Therapeutics (3) · SEC Filing (3) · Preclinical Stage (2) · Going Concern (2)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Net Loss (9 months) | $12.6M | Decreased from $38.8M in 2024, indicating improved operational efficiency. |
| Revenue (9 months) | $0 | No revenue generated in 2025, highlighting preclinical stage and reliance on financing. |
| Cash Balance | $3.0M | Increased from $1.7M at year-end 2024, bolstered by recent financing. |
| Gross Proceeds from Equity | $7.2M | Raised during the nine months ended September 30, 2025, crucial for liquidity. |
| Accumulated Deficit | $244.1M | Indicates significant historical losses and ongoing financial challenges. |
| Cash Used in Operating Activities (9 months) | $5.9M | Reduced from $12.3M in 2024, showing a lower cash burn rate. |
| Gain on Extinguishment of Debt | $734K | Positive impact on Q3 2025 results, contrasting with a $22.4M loss in Q3 2024. |
| Shares Outstanding | 7,848,889 | As of November 7, 2025, reflecting significant dilution from prior periods. |
| Cash | $4.3M | Increased from $1.7M at Dec 31, 2024, providing short-term liquidity. |
| Net Loss (6 months) | $11.3M | Reduced from $12.2M in prior year, but still substantial for a non-revenue company. |
| Private Placement Proceeds | $7.2M | Key financing event providing cash, but also dilutive. |
| Cash Used in Operations (6 months) | $4.6M | High burn rate, contributing to going concern doubts. |
| Revenue (6 months) | 0 | No revenue generated, highlighting preclinical stage and lack of commercial products. |
| Reverse Stock Split Ratio | 1-for-15 | A corporate action often taken to boost share price and maintain listing compliance. |
| Reporting Period End Date | 2025-03-31 | Indicates the end of the financial quarter being reported. |
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Ernexa Therapeutics Inc. (ERNAW)?
Ernexa Therapeutics Inc. has 33 recent SEC filings from Jan 2024 to Dec 2025, including 19 8-K, 6 10-Q, 2 DEF 14A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of ERNAW filings?
Across 33 filings, the sentiment breakdown is: 7 bearish, 25 neutral, 1 mixed. The dominant sentiment is neutral.
Where can I find Ernexa Therapeutics Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Ernexa Therapeutics Inc. (ERNAW) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Ernexa Therapeutics Inc.?
Key financial highlights from Ernexa Therapeutics Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for ERNAW?
The investment thesis for ERNAW includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Ernexa Therapeutics Inc.?
Key executives identified across Ernexa Therapeutics Inc.'s filings include Mr. Luther, Dr. Angel, Dr. Federoff, Sanjeev Luther.
What are the main risk factors for Ernexa Therapeutics Inc. stock?
Of ERNAW's 30 assessed filings, 6 were flagged high-risk, 16 medium-risk, and 8 low-risk.
What are recent predictions and forward guidance from Ernexa Therapeutics Inc.?
Forward guidance and predictions for Ernexa Therapeutics Inc. are extracted from SEC filings as they are enriched.